Cyprium Therapeutics, Inc.

Cyprium, a Fortress Biotech company, is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders.

Recent Press Releases

January 2020 :: Fortress Biotech Announces Rare Pediatric Disease Designation For CUTX-101 For The Treatment of Menkes Disease

September 2018 :: Fortress Biotech Announces Publication of Preclinical Data on AAV-ATP7A Gene Therapy Combined with CUTX-101 (Copper Histidinate) for Menkes Disease in Molecular Therapy: Methods & Clinical Development